Genetic predisposition and environmental factors associated with the development of atopic dermatitis in infancy: a prospective birth cohort study

Gallay, Caroline; Meylan, Patrick; Mermoud, Sophie; Johannsen, Alexandre; Lang, Caroline; Rivolta, Carlo; Christen‐Zaech, Stéphanie

doi:10.1007/s00431-020-03616-5

Cited by 10 publications

(7 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, AD was frequently associated with a personal or family history of atopy. The frequent association between AD and a personal or family history of atopy is well documented in the literature [20,21].…”

Section: Discussionmentioning

confidence: 95%

Atopic dermatitis in Senegalese children with skin phototype VI: Prevalence, clinical features, and risk factors of severity

Seck¹,

Diallo²,

Ndiaye³

et al. 2022

Our Dermatol Online

View full text Add to dashboard Cite

Background: Atopic dermatitis (AD) is the most common inflammatory skin disease of childhood. Yet, in sub-Saharan Africa, data on AD in children is scarce. Herein, we aimed to determine the prevalence, clinical features, and risk factors of severity of AD in Senegalese children with skin phototype VI. Materials and Methods: This was a cross-sectional study including children with AD and skin phototype VI younger than fifteen years old seen in two dermatology centers in Senegal over a period of six months. The diagnosis of AD was based on the United Kingdom Working Party (UKWP) criteria. The severity of AD was evaluated with SCORing of Atopic Dermatitis (SCORAD). Results: Among the 630 children consulted during the study period, 104 had AD, yielding a hospital prevalence of 16.5%. The mean age of children with AD was 36 months with a sex ratio of 1. A personal and family history of atopic disease was reported in 86.5% and 84.6% of the patients, respectively. Xerosis was the most common clinical feature, observed in 80.8% of. Post-inflammatory hyperpigmentation and keratosis pilaris were observed in 44.2% and 37.5%, respectively. Severe AD was noted in 12.5%. Risk factors associated with the severity of AD were exposure to incense smoke, an age of onset before 24 months, food allergies, and impetiginisatio. Daily use of shea butter was a protective factor. Conclusion: Our study showed a high hospital prevalence of AD in Senegalese children with skin phototype VI. The result observed with shea butter as a protective factor against severe AD is highly important, although it needs to be confirmed by randomized studies.

show abstract

Section: Discussionmentioning

confidence: 95%

Atopic dermatitis in Senegalese children with skin phototype VI: Prevalence, clinical features, and risk factors of severity

Seck¹,

Diallo²,

Ndiaye³

et al. 2022

Our Dermatol Online

View full text Add to dashboard Cite

show abstract

“…Roduit and co-workers showed that children’s risk of developing the early-persistent AD phenotype is five times greater in the case of parental allergies [ 77 ]. In addition, a birth cohort in Switzerland demonstrated that family history is the major risk factor for AD in Caucasians, regardless of even the most common filaggrin mutation, which was infrequent in this cohort [ 78 ].…”

Section: Discussionmentioning

confidence: 99%

Divergent Trends in the Prevalence of Children’s Asthma, Rhinitis and Atopic Dermatitis and Environmental Influences in the Urban Setting of Zagreb, Croatia

et al. 2022

View full text Add to dashboard Cite

Background: Previous studies have reported that the allergy epidemic in developed countries has reached its plateau, while a rise is expected in developing ones. Our aim was to compare the prevalence of allergic diseases among schoolchildren from the city of Zagreb, Croatia after sixteen years. Methods: Symptoms of asthma, allergic rhinitis (AR) and atopic dermatitis (AD) and risk factors were assessed using the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire. An allergic profile was determined by a skin prick test. Results: The prevalence of current, ever-in-a-lifetime and diagnosed AR of 35.7%, 42.5% and 14.9% and AD of 18.1%, 37.1% and 31.1% demonstrated a significant increase. The asthma prevalence has remained unchanged. The allergen sensitivity rate has remained similar, but pollens have become dominant. Mould and dog exposure are risks for asthma (OR 14.505, OR 2.033). Exposure to cat allergens is protective in AR (OR 0.277). Parental history of allergies is a risk factor in all conditions. Conclusion: Over sixteen years, the prevalence of AR and AD, but not of asthma, have increased. The proportion of atopy has remained high. The AR/AD symptom rise is probably a consequence of increased pollen sensitisation united with high particulate matter concentrations. The stable asthma trend could be a result of decreasing exposures to indoor allergens.

show abstract

“…[41][42][43] Family history of atopic dermatitis can be a significant risk factor for the development of disease and onset in early infancy or childhood can persist into adulthood in severe cases. [46][47][48] Other risk factors include starting complementary food after the age of 6 months, skin problems in the first few months of life, and elevated blood eosinophils (defined as at least 5% of total leukocytes) at 4 weeks of age. 48,49 Males younger than 2 years are also at an increased risk of developing atopic dermatitis.…”

Section: Disease Backgroundmentioning

confidence: 99%

Dupilumab (Dupixent)

CADTH

2023

cjht

View full text Add to dashboard Cite

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses dupilumab (Dupixent), 200 mg single-use syringe (200 mg per 1.14 mL) and 300 mg single-use syringe (300 mg per 2 mL), subcutaneous injection. Indication: For the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab can be used with or without topical corticosteroids.

show abstract

Genetic predisposition and environmental factors associated with the development of atopic dermatitis in infancy: a prospective birth cohort study

Cited by 10 publications

References 49 publications

Atopic dermatitis in Senegalese children with skin phototype VI: Prevalence, clinical features, and risk factors of severity

Atopic dermatitis in Senegalese children with skin phototype VI: Prevalence, clinical features, and risk factors of severity

Divergent Trends in the Prevalence of Children’s Asthma, Rhinitis and Atopic Dermatitis and Environmental Influences in the Urban Setting of Zagreb, Croatia

Dupilumab (Dupixent)

Contact Info

Product

Resources

About